Schall, Brown & Schwartz files Beta Bionics securities class action over iLet claims
The law firm says investors who bought Beta Bionics stock during the alleged class period may seek lead-plaintiff status by Nov. 3, 2026.
Schall, Brown & Schwartz LLP said it filed a federal securities class action against Beta Bionics, Inc. over alleged false and misleading statements about its iLet insulin pump and FDA issues.
The firm said the case seeks to represent buyers of Beta Bionics common stock during the alleged class period and that investors may be entitled to compensation. It also said investors have until Nov. 3, 2026, to seek appointment as lead plaintiff.
What the complaint alleges
According to the firm’s Sept. 8, 2026, release, the putative class period runs from July 30, 2025, through Feb. 24, 2026, inclusive. The complaint is titled Holtzman v. Beta Bionics, Inc. et al., No. 2:26-cv-09999, in the U.S. District Court for the Central District of California.
The release says the suit alleges violations of the Securities Exchange Act of 1934 by Beta Bionics and certain top executive officers. It says the company made statements about the safety, efficacy and commercial success of the iLet Bionic Pancreas insulin pump for diabetes treatment.
The release also says the FDA issued a Form 483 after inspecting the company’s manufacturing facility. A Form 483 is a document the agency uses to note observed conditions that may violate federal manufacturing rules.
Schall, Brown & Schwartz said Beta Bionics later described the observations as involving only reporting criteria for customer complaints and minor events that did not require medical intervention. The release alleges later information showed broader issues involving the company’s quality management system, its investigation and correction of known device malfunctions, risk analysis for the device and unreported serious injuries.
Background and context
The release identifies the iLet as Beta Bionics’ sole commercialized product and says the company is listed on Nasdaq under the ticker BBNX. It also says the stock declined as the alleged truth emerged, though the release does not provide a specific price move or date for each decline.
The law firm said investors who purchased BBNX shares during the class period may participate without out-of-pocket fees or costs, subject to the terms described in the filing and any court action on lead-plaintiff status.
What the firm said
The release says interested investors can contact Brian Schall, David Schwartz and Adam Rosen at Schall, Brown & Schwartz LLP in Los Angeles. It also says the complaint was filed on behalf of purchasers of Beta Bionics common stock.
What happens next
The next deadline in the release is Nov. 3, 2026, when investors seeking appointment as lead plaintiff must act. The lawsuit will then proceed in federal court unless the parties reach a resolution or the court takes another action.
Sources
Editorial note: This article was prepared with AI assistance and includes source attribution for reader review.
Comments ()